Literature DB >> 1054261

Skin changes secondary to hydroxyurea therapy.

B J Kennedy, L R Smith, R W Goltz.   

Abstract

Hydroxyurea is an effective agent in the treatment of chronic myelogenous leukemia. The toxic reactions have included myelosuppression and megaloblastosis. During long-term maintenance therapy, dermatologic alterations occurred in seven of 20 patients and consisted of partial alopecia, increased pigmentation, scalings, atrophy of the skin and subcutaneous tissues, nail changes, and erythema of the face and hands. The histologic changes were similar to those seen in lichen planus. These observations were a factor leading to the use of hydroxyurea in the treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1054261

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  11 in total

Review 1.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Reversible hyperpigmentation associated with high dose hydroxyurea.

Authors:  G Majumdar; S E Heard; N G Slater
Journal:  BMJ       Date:  1990-06-02

Review 3.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

4.  The skin biopsy in the diagnosis of acute graft-versus-host disease in man.

Authors:  G E Sale; K G Lerner; E A Barker; H M Shulman; E D Thomas
Journal:  Am J Pathol       Date:  1977-12       Impact factor: 4.307

Review 5.  Drug eruptions.

Authors:  S K Goolamali
Journal:  Postgrad Med J       Date:  1985-10       Impact factor: 2.401

6.  Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

Authors:  Mehran Karimi; Sezaneh Haghpanah; Ali Farhadi; Majid Yavarian
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

7.  Acute mucocutaneous toxicity following high-dose hydroxyurea.

Authors:  H Brincker; B E Christensen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)).

Authors:  Victoria K Shanmugam; Sean McNish; Nawar Shara; Katherine J Hubley; Bhaskar Kallakury; David M Dunning; Christopher E Attinger; John S Steinberg
Journal:  J Foot Ankle Surg       Date:  2013-08-14       Impact factor: 1.286

Review 9.  [Ulcers following therapy with hydroxyurea. Three case reports and review of the literature].

Authors:  S Boneberger; R A Rupec; T Ruzicka
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

10.  Hydroxyurea induced perimalleolar ulcers.

Authors:  Kavitha Saravu; Praveen Velappan; Naik Lakshmi; Barkur Ananthakrishna Shastry; Joseph Thomas
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.